Six week, double-blind, placebo controlled phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.

Trial Profile

Six week, double-blind, placebo controlled phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Dec 2011 Planned number of patients (221) added as reported by ClinicalTrials.gov record (Extension trial: NCT00265382).
    • 05 Dec 2011 Planned number of patients (221) added as reported by ClinicalTrials.gov record (Extension trial: NCT00265382).
    • 05 Dec 2011 Planned end date (Jun 2009) added as reported by ClinicalTrials.gov record (Extension trial: NCT00265382).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top